BRIEF-Cervomed’S Neflamapimod Elected For Inclusion In Uk Experts-Als Platform

CervoMed Inc. 0.00% Pre

CervoMed Inc.

CRVO

4.04

4.04

0.00%

0.00% Pre

- CervoMed Inc CRVO.O:

  • CERVOMED’S NEFLAMAPIMOD ELECTED FOR INCLUSION IN UK EXPERTS-ALS PLATFORM DESIGNED TO PRIORITIZE PROMISING TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS

  • CERVOMED INC - FIRST ALS PATIENT EXPECTED TO BE DOSED BY END OF 2026

  • CERVOMED: MAINTAIN FOCUS ON DLB, TAKE STEPS TO INITIATE PLANNED PHASE 3 TRIAL LATER THIS YEAR

Source text: ID:nGNX2TdN7K

Further company coverage: CRVO.O